The U.S. Minimal Residual Disease (MRD) testing market is witnessing significant growth, driven by its vital role in cancer diagnostics and treatment monitoring, especially for hematologic malignancies like leukemia and lymphoma. By detecting traces ...
Markdown supported · ⌘↵ to post
No responses yet.